Cooling sleeve could shield cancer patients from chemo nerve pain
NCT ID NCT05606068
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a special cooling and compression sleeve (Paxman Limb Cryocompression System) worn during chemotherapy to prevent nerve damage, a common side effect. About 200 cancer patients receiving weekly paclitaxel will use the device for up to 4 hours per session. Researchers will check for side effects and measure changes in nerve symptoms using questionnaires.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Paxman Limb Cryocompression System (a cooling and compression sleeve)
- What this could lead to
- If it works, this could give cancer patients a way to prevent painful nerve damage from chemotherapy, improving their quality of life during and after treatment.
- What could go wrong
- This is an early expansion study with no control group, so results may not prove effectiveness. The device may cause discomfort or fail to prevent neuropathy in all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2022
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 21- 80 years. * Signed informed consent from patient or legal representative * Scheduled to receive weekly paclitaxel chemotherapy * Patients may receive other chemotherapy drugs alongside taxane e.g. Platinum/Herceptin. Exclusion Criteria: * Open skin wound or ulcers of the limbs * History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes * Pregnant woman * A score of more than 5 in Total Neuropathy Score (TNS) at baseline for cancer patients
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Curie Oncology, Mount Elizabeth Novena Specialist Centre
NOT_YET_RECRUITINGSingapore, 329563, Singapore
-
National University Hospital
RECRUITINGSingapore, 119074, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success
- Could a frailty score predict which older cancer patients survive intensive care?